However , it can significantly decrease postintervention and reduction data of FPG , FI , HbA1c , and HOMA-IR .
Heterogeneity was eliminated by subgroup analysis according to baseline BMI .
There was no significant difference in the amelioration of QUICKI between the ITC and control groups .
However , the difference was statistically significant and the heterogeneity was eliminated after subgroup analysis according to intakes of ITC .
Conclusion Supplementation of ITC can ameliorate IR in T2DM , especially in obese T2DM patients , but the effects are controversial in obese patients
Background Insulin resistance ( IR ) is a physiological condition related to type 2 diabetes mellitus ( T2DM ) and obesity , which is associated with high blood insulin and glucose .
Inulin-type carbohydrate ( ITC ) is a kind of fermentable fructan that can reduce glucose and ameliorate IR in an animal model , but the effect in clinical trials is controversial .
Objective The authors conducted a systematic literature review to evaluate the effect of ITC supplementation in ameliorating IR in T2DM and obese patients .
Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial.
Studies on humans with diabetes mellitus showed that the crosstalk between the intestinal microbiota and the host has a key role in controlling the disease . The aim of this study was to evaluate the effects of sodium butyrate and high performance inulin supplementation simultaneously or singly on glycemic status , lipid profile , and glucagon-like peptide 1 level in adults with type 2 diabetes mellitus . Sixty patients were recruited for the study . The participants were r and omly allocated , using r and omized block procedure , to one of the four treatment groups ( A , B , C , or D ) . Group A received sodium butyrate capsules , group B received inulin supplement powder , group C was exposed to the concomitant use of inulin and sodium butyrate , and group D consumed placebo for 45 consecutive days . Markers of glycemia , lipid profile , and glucagon-like peptide 1 were measured pre- and post-intervention . Dietary supplementation in groups A , B , and C significantly reduced diastolic blood pressure in comparison with the placebo group ( p<0.05 ) . Also , intra-group statistical analysis showed that only treatment with sodium butyrate + inulin ( group C ) significantly reduced fasting blood sugar ( p=0.049 ) and waist to hip ratio ( p=0.020 ) . Waist circumference in groups B and C reduced significantly after the intervention ( p=0.007 and p=0.011 ; respectively ) . The post hoc Tukey tests showed significant increase in glucagon-like peptide 1 concentration in groups A and C in comparison with group D ( p<0.05 ) . The results suggest that inulin supplementation may be useful to diabetic patients and these effects could be increased with butyrate supplement
However , it can significantly decrease postintervention and reduction data of FPG , FI , HbA1c , and HOMA-IR .
Heterogeneity was eliminated by subgroup analysis according to baseline BMI .
There was no significant difference in the amelioration of QUICKI between the ITC and control groups .
However , the difference was statistically significant and the heterogeneity was eliminated after subgroup analysis according to intakes of ITC .
Conclusion Supplementation of ITC can ameliorate IR in T2DM , especially in obese T2DM patients , but the effects are controversial in obese patients
Background Insulin resistance ( IR ) is a physiological condition related to type 2 diabetes mellitus ( T2DM ) and obesity , which is associated with high blood insulin and glucose .
Inulin-type carbohydrate ( ITC ) is a kind of fermentable fructan that can reduce glucose and ameliorate IR in an animal model , but the effect in clinical trials is controversial .
Objective The authors conducted a systematic literature review to evaluate the effect of ITC supplementation in ameliorating IR in T2DM and obese patients .